Chinese Medicine Regulatory Office

The “Forum on Drug Evaluation and Inspection affairs in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA)” (“The Forum”), organised by the Guangdong-Hong Kong-Macao Greater Bay Area Center for Drug Evaluation and Inspection (GBA Center) of National Medical Products Administration (NMPA), was held on 9 November 2022. Representatives from the Center for Drug Evaluation of NMPA, Center for Food and Drug Inspection of NMPA, Guangdong Provincial Medical Products Administration (GDMPA), Department of Health of HKSAR Government, Pharmaceutical Administration Bureau of Macao SAR Government (ISAF), Administration for Market Regulation of 9 cities in GBA and pharmaceutical enterprises in GBA were invited to attend the Forum. Officers from the Drug Office and the Chinese Medicine Regulatory Office of the Department of Health attended the Forum online. The objective of the Forum was to promote regional drug research and transformation of innovative achievement within the GBA, to establish a coordination mechanism among different regulatory authorities and a system for regional drug evaluation and inspection, strengthen the technical support for drug registration and to serve the innovative development of pharmaceutical industry in GBA. Through the presentations given by the respective representatives and exchange of views, participants gained a better understanding of the work of the GBA Center and the drug regulatory authorities in GBA, as well as the relevant pharmaceutical industries.